Best of ASCO 2022 | Event in Greece

69
Speakers
1
Days
242
Registrations
12
Sponsors

Chairs: N. Tsoukalas, A. Tzovaras

12.00-12.20 Abstract 12000: Impact of acetaminophen on the efficacy of immunotherapy in cancer patients  

Abstract 12023: Vitamin D insufficiency as a peripheral neuropathy risk factor in white and black patients in SWOG 0221  

Al. Lazarou 

 

12.20-12.40 Abstract 507: Long-term outcomes of adjuvant denosumab in breast cancer: Fracture reduction and survival results from 3,425 patients in the randomised, double-blind, placebo-controlled ABCSG-18 trial

Abstract 8504: Comparison of quality of life in patients randomized to high-dose once daily (QD) thoracic radiotherapy (TRT) with standard twice daily (BID) TRT in limited stage small cell lung cancer (LS-SCLC) on CALGB 30610 (Alliance, Sub-study CALGB 70702)

F. Folinas 

 

12.40-13.00 Abstract 6501: The PACES Study: A controlled before and after pragmatic trial of a cancer clinic based intervention to increase early referral to specialist palliative care

Abstract 6500: The effect of a multilevel community health worker-led intervention on health-related quality of life, patient activation, acute care use, and total costs of care: A randomized controlled trial

D. Papageorgiou

 

13.00-13.15 Discussion

Chairs: L. Florentin, E. Saloustros

13.15-13.45 Abstract 5007: Defining germline genetics of germ cell tumor: Implications for genetic testing and clinical management

Abstract 10501: Rates of germline genetic testing and DNA damage response mutations found through population-based recruitment of men with incident metastatic prostate cancer

Abstract 10502: Mutation spectrum and rates of variants of uncertain significance among African American males undergoing prostate cancer germline testing: Need for equity in genetic testing

A. Assi 

 

13.45-14.00 Discussion

Chairs: Ε. Razis, G. Rigakos

15.00-15.20 Abstract 2006: Baseline tumor genomic and gut microbiota association with clinical outcomes in newly diagnosed glioblastoma (GBM) treated with atezolizumab in combination with temozolomide (TMZ) and radiation

Abstract 2001: Randomized phase II/III trial of veliparib or placebo in combination with adjuvant temozolomide in newly diagnosed glioblastoma (GBM) patients with MGMT promoter hypermethylation (Alliance A071102)

A. Tsiara

 

15.20-15.40 Abstract LBA 2002: Primary analysis of a phase II trial of dabrafenib + trametinib (dab + tram) in BRAF V600-mutant pediatric low-grade glioma (pLGG)

Abstract 2003: Prognostic validation and refinement of a classification system for extent of resection in glioblastoma: A report of the RANO resect group

S. Talagani 

 

15.40-16.00 Discussant       E. Razis               

Chairs: A. Stribakos, L. Vamvakas

At the Intersection of Biomarkers and Health Equity for Older Adults With Cancer 

Ch. Panopoulos

Chairs: Ch. Andreadis, A. Kotsakis

16.30-16.50 Abstract 6015: Refining nodal category in TNM staging with extent of extranodal extension for oral cavity squamous cell carcinoma

Abstract 6000: Radiotherapy alone versus concurrent chemoradiotherapy in intermediate risk nasopharyngeal carcinoma: A multicentre, open-label, non-inferiority, randomised phase III trial

P. Katsaounis

 

16.50-17.10 Abstract 6004: An open label non-inferiority phase III RCT of weekly versus three weekly cisplatin and radical radiotherapy in locally advanced head and neck squamous cell carcinoma (ConCERT trial)

Abstract 6006: Association of plasma tumor tissue modified viral HPV DNA (TTMV) with tumor burden, treatment type, and outcome: A translational analysis from NRG-HN002.

E. Biziota

 

17.10-17.20 Discussant     A. Psyrri

Chairs: Ch. Cristodoulou, D. Tryfonopoulos

17.40-18.25 Abstract 500: Final results from a phase III randomized clinical trial of adjuvant endocrine therapy ± chemotherapy in women ≥ 70 years old with ER+ HER2- breast cancer and a high genomic grade index: The Unicancer ASTER 70s trial

Abstract LBA501: LUMINA: A prospective trial omitting radiotherapy (RT) following breast conserving surgery (BCS) in T1N0 luminal A breast cancer (BC)

Abstract 506: Adding ovarian function suppression to tamoxifen in young women with hormone-sensitive breast cancer who remain premenopausal or resume menstruation after chemotherapy: 8-year follow-up of the randomized ASTRRA trial

K. Rapti

 

18.25-18.40 Discussant          A. Matikas

Chairs: V. Barbounis, Th. Foukakis

18.40-19.10 Abstract 504: Pathologic complete response (pCR) rates for HR+/HER2- breast cancer by molecular subtype in the I-SPY2 Trial

Abstract LBA3: Trastuzumab deruxtecan (T-DXd) vs treatment of physician’s choice (TPC) in patients (pts) with HER2-low unresectable and/or metastatic breast cancer (mBC): results of DESTINY-Breast04, a randomized, phase 3 study

Abstract LBA1001: Primary Results From TROPiCS-02: A Randomized Phase 3 Study of Sacituzumab Govitecan (SG) vs Treatment of Physician’s Choice (TPC) in Patients (Pts) With Hormone Receptor-Positive/ HER2-Negative (HR+/HER2-) Advanced Breast Cancer

S. Karageorgopoulou

 

19.10-19.30 Abstract LBA1004: A randomized phase II trial of fulvestrant or exemestane with or without Ribociclib after progression on Anti-estrogen therapy plus cyclin-dependent kinase 4/6 inhibition (CDK 4/6i) in patients (pts) with unresectable or hormone receptor positive (HR+), HER2 negative metastatic breast cancer (MBC): MAINTAIN trial

Abstract 1005: Fulvestrant plus capivasertib versus fulvestrant plus placebo after relapse or progression on an aromatase inhibitor in metastatic, estrogen receptor-positive breast cancer (FAKTION): Overall survival and updated progression free survival data with enhanced biomarker analysis.

 V. Aidarinis

 

19.30-19.50 Discussant        E. Galani 

Chairs: M. Nikolaou, N. Xenidis

09.00-09.30 Abstract 2501: First-in-human study of SRF388, a first-in-class IL-27 targeting antibody, as monotherapy and in combination with pembrolizumab in patients with advanced solid tumors

Abstract 2505: Phase 1 first-in-human study of anti–ILT3 mAb MK-0482 as monotherapy and in combination with pembrolizumab in advanced solid tumors: Dose escalation results

Abstract 2506: A phase 1b, multicenter, dose-escalation study of subasumstat (TAK-981) in combination with pembrolizumab in patients (pts) with advanced solid tumors

E. Kontopodis

 

09.30-09.40 Discussion

Chairs: O. Katopodi, G. Papaxoinis

09.40-10.00 Abstract LBA100: Adjuvant chemotherapy guided by circulating tumor DNA analysis in stage II colon cancer: The randomized DYNAMIC Trial

Abstract LBA5: Single agent PD-1 blockade as curative-intent treatment in mismatch repair deficient locally advanced rectal cancer

N. Vardakis

 

10.00-10.20 Abstract LBA1: Panitumumab (PAN) plus mFOLFOX6 versus bevacizumab (BEV) plus mFOLFOX6 as first-line treatment in patients with RAS wild-type (WT) metastatic colorectal cancer (mCRC): results from the phase 3 PARADIGM trial

Abstract 3503: Improve Study: Randomized intermittent or continuous FOLFIRI/PANI for first-line treatment of patients (pts) with RASwt colorectal cancer

A. Markou

 

10.20-10.40 Abstract LBA 4011: Nimotuzumab combined with gemcitabine versus gemcitabine in K-RAS wild-type locally advanced or metastatic pancreatic cancer: A prospective, randomized-controlled, double-blinded, multicenter and phase III clinical trial

Abstract 4006: Trastuzumab deruxtecan (T-DXd; DS-8201) in patients (pts) with HER2-expressing unresectable or recurrent biliary tract cancer (BTC): An investigator-initiated multicenter phase 2 study (HERB trial)

I. Samaras

 

10.40-11.00 Discussant          G. Papaxoinis

Chairs: I. Athanasiadis, M. Liontos

Small Molecule Inhibition of KRAS: Opportunities and Challenges

V. Papadopoulos 

Chairs: D. Bafaloukos, D. Ziogas

12.00-12.20 Abstract LBA 9500: Distant metastasis-free survival with pembrolizumab versus placebo as adjuvant therapy in stage IIB or IIC melanoma: the phase 3 KEYNOTE-716 study

Abstract 9502: Neoadjuvant PD-1 blockade in patients with resectable desmoplastic melanoma (SWOG 1512).

J. Duran - Moreno

 

12.20-12.40 Abstract 9505: Nivolumab (NIVO) + relatlimab (RELA) versus NIVO in previously untreated metastatic or unresectable melanoma: OS and ORR by key subgroups from RELATIVITY-047

Abstract 9507: Nivolumab (NIVO) + tacrolimus (TACRO) + prednisone (PRED) +/- ipilimumab (IPI) for kidney transplant recipients (KTR) with advanced cutaneous cancers

Aik. Kotsori

 

12.40-13.00 Discussant.         A. Laskarakis

Chairs: S. Fortis, I. Pateras

Beyond Checkpoint Inhibitors: Next-Generation Immunotherapies   

A. Boutis

Chairs: V. Karavasilis, G. Kesisis

14.30-14.50 Abstract LBA2: Phase III assessment of topotecan & cyclophosphamide and high-dose ifosfamide in rEECur, an international randomised controlled trial of chemotherapy for the treatment of recurrent and primary refractory Ewing sarcoma (RR-ES)

Abstract 101: Circulating tumor DNA (ctDNA) analyses of the phase III VOYAGER trial: KIT mutational landscape and outcomes in patients with advanced gastrointestinal stromal tumor (GIST)

S. Kokkali

 

14.50-15.10 Abstract 11500: Primary efficacy and safety of letetresgene autoleucel (lete-cel; GSK3377794) pilot study in patients with advanced and metastatic myxoid/round cell liposarcoma (MRCLS)

Abstract 11506: A phase Ib/II study of the combination of lenvatinib (L) and eribulin (E) in advanced liposarcoma (LPS) and leiomyosarcoma (LMS) (LEADER): Efficacy updates

A. Kyriazoglou

 

15.10-15.30 Discussant             V. Karavasilis

Chairs: Ch. Papadimitriou, V. Papadopoulos

15.30-15.50 Abstract LBA5500: ATHENA-MONO: A randomized, placebo-controlled, double-blind, phase 3 trial evaluating rucaparib monotherapy as maintenance treatment following response to frontline platinum-based chemotherapy in ovarian cancer

Abstract 5512: Mirvetuximab sorvatansine (MIRV) in patients with platinum-resistant ovarian cancer with high folate receptor alpha: FRa expression: characterization of antitumor activity in the SORAYA study

M. Rovithi 

 

15.50-16.10 Abstract 5509: Dostarlimab in advanced/recurrent (AR) mismatch repair deficient/microsatellite instability-high or proficient/stable (dMMR/MSI-H or MMRp/MSS) endometrial cancer (EC): the GARNET study

Abstract 5507: Tisotumab vedotin (TV) + pembrolizumab (pembro) in first-line (1L) recurrent or metastatic cervical cancer (r/mCC): Interim results of ENGOT Cx8/GOG 3024/innovaTV 205

M. Drizou 

 

16.10-16.30 Discussant.         R. Zakopoulou

Chairs: H. Kotteas, G. Oikonomopoulos

17.00-17.30 Abstract LBA8507: SKYSCRAPER-02: Primary results of a phase III, randomized, double-blind placebo-controlled study of atezolizumab (atezo) + carboplatin + etoposide (CE) with or without tiragolumab (tira) in patients (pts) with untreated extensive-stage small cell lung cancer (ES-SCLC)

Abstract 8500: Two cycles versus three cycles of neoadjuvant sintilimab plus platinum-doublet chemotherapy in patients with resectable non-small-cell lung cancer (neoSCORE): A randomized, single center, two-arm phase II trial Abstract 8512: EORTC-1416-LCG/ETOP 8-15 - PEARLS/KEYNOTE-091 study of pembrolizumab versus placebo for completely resected early-stage non-small cell lung cancer (NSCLC): Outcomes in subgroups related to surgery, disease burden, and adjuvant chemotherapy use

E. Eleutherakis - Papaiakovou

 

17.30-18.00 Abstract 9000: Outcomes of anti-PD-(L)1 therapy with or without chemotherapy (chemo) for first-line (1L) treatment of advanced non-small cell lung cancer (NSCLC) with PD-L1 score ≥50%: FDA pooled analysis

Abstract 9004: Overall survival from a phase II randomized study of ramucirumab plus pembrolizumab versus standard of care for advanced non-small cell lung cancer previously treated with immunotherapy: Lung-MAP non-matched sub-study S1800A

Abstract 102: Largest evaluation of acquired resistance to sotorasib in KRAS p.G12C-mutated non-small cell lung cancer (NSCLC) and colorectal cancer (CRC): Plasma biomarker analysis of CodeBreaK100

D. Stefanou

 

18.00-18.30 Discussant               An. Grivas

Chairs: E. Lianos, K. Tsapakidis

18.30-18.50 Abstract LB4500: EVEREST: EVErolimus for Renal cancer Ensuing Surgical Therapy, A phase III study

Abstract 4513: Pembrolizumab (pembro) plus axitinib (axi) versus sunitinib as first-line therapy for advanced clear cell renal cell carcinoma (ccRCC): Analysis of progression after first subsequent therapy in KEYNOTE-426

Abstract 4502: The relationship between health-related quality of life (HRQoL) and clinical outcomes in patients with advanced renal cell carcinoma (aRCC) in CheckMate (CM) 214

Th. Tegos

 

18.50-19.10 Discussant           K. Koutsoukos

Chairs: Ph. Koinis, Ch. Kourousis, M. Tsiatas

19.10-19.40 Abstract 4516: Long-term outcomes in EV-301: 24-month findings from the phase 3 trial of enfortumab vedotin versus chemotherapy in patients with previously treated advanced urothelial carcinoma

Abstract LBA 5004: Updated overall survival outcomes in ENZAMET (ANZUP 1304), an international, cooperative group trial of enzalutamide in metastatic hormone-sensitive prostate cancer (mHSPC)

Abstract 5000: TheraP: 177Lu-PSMA-617 (LuPSMA) versus cabazitaxel in metastatic castration resistant prostate cancer (mCRPC) progressing after docetaxel: Overall survival aftermedian follow-up of 3 years (ANZUP 1603)

N. Asimakopoulou 

 

19.40-20.00 Discussan           M. Tsiatas

Aidarinis V.
Resident of Medical Oncology University Hospital of Larissa
Andreadis Ch.
MD, PhD, Medical Oncologist, Head, 3rd Department Clinical Oncology, Theagenion Cancer Hospital, Thessaloniki, Greece
Asimakopoulou N.
MD, PhD, Resident of Medical Oncology, Evangelismos Hospital, Athens, Greece
Assi A.
Medical Oncologist and Clinical Research Fellow, Henry Dunant Hospital Center and Attikon University Hospital
Athanasiadis I.
Medical Oncologist, Director of Oncology Clinic Mitera Hospital (Hygeia Group), Athens, Greece / Ass. Professor of Oncology, Northwestern University, Chicago, USA
Bafaloukos D.
MD, PhD, Medical Oncologist, Emeritus Professor of University of W.A., Director of 1st Oncology Department, Metropolitan Hospital, Athens
Barbounis V.
MD, PhD, Medical Oncologist, Director of the 3rd Oncology Clinic, Metropolitan Hospital, Piraeus, Greece
Biziota Ι.
MD, PhD, Medical Oncologist, University Hospital of Alexandroupoli
Boutis A.
MD, PhD, Consultant Medical Oncologist, 1 st Dpt. Of Medical Oncology, Theageneio Cancer Hospital, Thessaloniki
Christodoulou C.
Director, 2nd Oncology Clinic, Metropolitan Hospital, Piraeus, Greece
Drizou M.
Medical Oncologist, 2nd Oncology department, Metropolitan Hospital, Athens, Greece
Duran Moreno J.
MD, MSc, Medical Oncologist, Oncology Unit, 4th Department of Internal Medicine, Medical School, National and Kapodistrian University of Athens, Athens, Greece
Eleftherakis-Papaiakovou E.
ΜD, MSc, PhD, Medical Oncologist, Registrar at Oncology Unit, Dpt. Of Clinical Therapeutics, Alexandra Hospital, Athens, Greece
Florentin L.
BSc, PhD, ErCLG, Clinical Laboratory Geneticist, Director of Genetics, A-Lab Genetics and Genomics Center, Athens
Folinas K.
MD, Resident of Medical Oncology, Evangelismos General Hospital, Athens
Fortis S.
M.Sc, PhD, Postdoctoral Researcher, Cancer Immunology and Immunotherapy Center, Saint Savas Cancer Hospital, Athens, Greece
Foukakis T.
Associate Professor, Senior Consultant, Department of Oncology-Pathology, Karolinska Institutet, Breast Center, Karolinska University Hospital, Sweden
Galani E.
MD, Professor of Oncology and Sandr a J. Schulze Professor of Nov el Therapeutics, Executive Dean of Development, Mayo Clinic, Rochester, Minnesota, USA - Chair, Neuro-Oncology Committee, Alliance for Clinical Trials in Oncology
Grivas An.
MD, Medical Oncologist Consultant, 2nd department of Medical Oncology Agios Savvas Anticancer Hospital, Athens
Karageorgopoulou S.
MD, PhD, Medical Oncologist, Director, 3rd Medical Oncology Department, IASO Clinic, Athens
Karavasilis V.
Consultant Medical Oncologist The London sarcoma Service at University College London Hospital Honorary Associate Professor of Oncology, Cancer Institute, University College London
Katopodis Ourania
MD, PhD, Consultant Medical Oncologist, Chairman of the Oncolo gy Committee, Department of Medical Oncology, “Athens Euroclinic Hospital”
Katsaounis P.
MD, Medical Oncologist, Metropolitan General Hospital, Athens, Greece
Kesisis G.
Παθολόγος - Ογκολόγος, Κλινική Άγιος Λουκάς, Θεσσαλονίκη
Koinis F.
MD, PhD, Assistant Professor of Medical Oncology, Faculty of Medicine, School of Health Sciences, University of Thessaly, Larissa, Greece
Kokkali S.
MD, MSc, Consultant Medical Oncologist, Hippocratio General Hospital of Athens
Kontopodis E.
MD, Medical Oncologist, Attending Physician, Venizeleion General Hospital of Heraklion
Kotsakis A.
MD, PhD, Associate Professor of Medical Oncology, Director of Department of Medical Oncology, University Hospital of Larisa, Thessaly, Greece
Kotsori Aik.
MD, Consultant Medical Oncologist, Clinical Research Fellow, Royal Marsden Hospital, London UK / Head of the 6th Department of Medical Oncology, Metropitan General Hospital, Athens
Kotteas Ε.
Associate Professor of Oncology, National & Kapodistrian University of Athens
Kourousis Ch.
MD, PhD, Head of the Medical Oncology Dpt., General Hospital Iasis, Chania, Crete
Koutsoukos K.
MD, MCs, Medical Oncologist, Alexandra Hospital, National Kapodistrian University of Athens, Eugenideio Hospital, Athens
Kyriazoglou A.
MD, PhD, Medical Oncologist, National & Kapodistrian University of Athens, 2nd Propaedeutic Department of Medicine, Attikon University Hospital, Athens, Greece
Laskarakis A.
MD, MSc, Medical Oncologist, Director, Oncology Department, Medical Center of Athens, Athens
Lazarou Al.
MD, Resident of Medical Oncology,University Hospital of Larissa
Lianos E.
MD, Medical Oncologist, Sr Consultant - Medical Oncology Dpt., METAXA Memorial Cancer Center Hospital, Piraeus - Greece
Liontos M.
PhD, Medical Oncologist, Consultant, Department of Clinical Therapeutics, Alexandra Hospital, Athens, Greece
Markou A.
PhD, Assistant Professor, Lab of Analysis Circulating Tumor Cells (ACTC), Lab of Analytical Chemistry, Dept of Chemistry, National and Kapodistrian University of Athens, Greece
Matikas A.
Associate Professor of Oncology, Karolinska Institutet, Stockholm, Sweden
Nikolaou Μ.
MD, MSc, PhD, Medical Oncologist, Anti - Cancer Hospital Agios Savvas, Athens, Greece
Oikonomopoulos G.
Consultant in Medical Oncology, MSc, 2nd Oncology Department, Metropolitan Hospital, Athens, Greece
Panopoulos Ch.
MD, PhD, Medical Oncologist, Director of 4th Dpt. of Medical Oncology, Euroclinic Athens
Papadimitriou Ch.
Professor of Medical Oncology, Aretaieion Hospital
Papadopoulos V.
MD, Oncologist, Consultant, Department of Oncology, University Hospital, Larisa, Greece
Papageorgiou D.
Assistant Professor, Nursing Department University of Peloponese, President H.O.N.S. ESNE
Papaxoinis G.
Consultant Medical Oncologist, Agios Savvas Anticancer Hospital, National and Kapodistrian University of Athens, Greece
Pateras I.
Bsc, MD, PhD, Pathologist, Assistant Professor, Medical School, National and Kapodistrian University of Athens, Athens, Greece
Psyrri A.
MD, PhD, Medical Oncologist, Professor, Medical School, University of Athens, Greece
Rapti K.
MD, MSc, Consultant Medical Oncologist, 251 General Airforces Hospital
Razis E.
MD, PhD, Medical Oncologist, Director, 3rd Oncology Department, Hygeia Hospital, Director, Contemporary Oncology Team, Athens
Rigakos G.
MD, MSc, Medical Oncologist, Consultant, 3rd Oncology Department, Hygeia Hospital, Athens
Rovithi M.
Medical Oncologist, Agios Nikolaos General Hospital, Crete, Greece
Saloustros E.
Assistant Professor of Oncology, Faculty of Medicine, School of Health Sciences, University of Thessaly, Larissa
Samaras I.
MD, Medical Oncologist, University Hospital of Larissa, Greece
Stefanou D.
MD, PhD, Mesical Oncologist, 1rst Department of Internal Medicine, Laiko General Hospital, Athens, Greece
Stribakos A.
Medical Oncologist, Director of 5th Internal Medicine - Oncology Clinic HYGEIA
Talagani S.
Medical Oncology Resident, Agios Savvas General Anticancer Hospital of Athens
Tegos Th.
Medical Oncologist, PhD, Evangelismos General Hospital, Athens, Greece
Tryfonopoulos D.
MD, MSc, PhD, Medical Oncologist, Anti-Cancer Hospital Agios Savvas, Athens, Greece
Tsapakidis K.
Medical Oncologist, University Hospital of Larissa, Greece
Tsiara A.
Medical Oncologist, 5th Clinic of Medical Oncology, Hygeia Hospital, Athens
Tsiatas M.
MD, PhD, BSc (Biol), Director Medical Oncologist, Department o f Medical Oncology and Clinical Trials Unit, Athens Medical Center
Tsoukalas N.
MD, MSc, PhD, Medical Oncologist, MSc in Bioinformatics, Deput y Director, Oncology Department, 401 General Military Hospital, Consultant, Henry Dunant Hospital Center, Athens Greece
Tzovaras A.
Medical Oncologist Consultant, Agios Savvas Anticancer Hospital, Athens
Vamvakas L.
MD, PhD, Medical Oncologist, Director of Oncology Department, PAGNI Hospital, Heraklion, Crete
Vardakis N.
Consultant in Chief, Medical Oncologist, University Hospital of Heraklion, Crete
Xenidis N.
Associate Professor of Clinical Oncology, Democritus University of Thrace, Greece
Zakopoulou R.
MD, PhD, Medical Oncologist, National and Kapodistrian University of Athens, 2nd Propaedeutic Department of Medicine, A TTIKON University Hospital, Athens, Greece
Ziogas D.
MD, PhD, Academic Scholar in Medical Oncology 1st Department of Internal Medicine, Laikon General Hospital, School of Medicine, National and Kapodistrian University of Athens, Athens

Αφού έχετε κάνει σύνδεση με τους κωδικούς σας (σε περίπτωση που δεν έχετε κωδικούς ακολουθήστε τη διαδικασία δημιουργίας λογαριασμού), πατήστε το κουμπί "Εγγραφείτε στην εκδήλωση".

Η καταγραφή του χρόνου παρακολούθησης αναγράφεται στη δεξιά πλευρά της σελίδας της εκδήλωσης που παρακολουθείτε. Η μέτρηση του χρόνου παρακολούθησης ξεκινάει εφόσον έχετε κάνει Subscription και εφόσον η εκδήλωση έχει ξεκινήσει. Η προβολή αυτού του πεδίου, πληροφορεί τον χρήστη για τον χρόνο (minutes) που έχει παρακολουθήσει.

Η εμφάνιση του pop-up window εξυπηρετεί στη διαφάνεια και στην αξιοπιστία των δεδομένων, που τελικά συλλέγονται μετά το πέρας της εκδήλωσης. Η διάρκεια εμφάνισης ενός pop-up window κατά την παρακολούθηση μίας live εκδήλωσης, είναι δύο λεπτά ενώ η επανάληψη εμφάνισης είναι περίπου ανά εξήντα λεπτά. Σε αυτό το διάστημα ο συμμετέχοντας της εκδήλωσης οφείλει να "απαντήσει", επιλέγοντας μία από τις δύο συνθήκες που εμφανίζονται στο pop-up window. Σε διαφορετική περίπτωση, το σύστημα θα διακόψει την καταγραφή του χρόνου παρακολούθησης.

Αφού έχετε κάνει σύνδεση και εγγραφή στην εκδήλωση, μπορείτε να υποβάλετε τις ερωτήσεις σας προς τους ομιλητές στο πεδίο που εμφανίζεται ακριβώς δίπλα στο παράθυρο αναμετάδοσης

Για να λάβετε το πιστοποιητικό σας, απαραίτητη προϋπόθεση είναι να έχετε επιλέξει το πεδίο "Εγγραφείτε στην εκδήλωση" καθώς και να έχετε παρακολουθήσει το 60% των συνολικών ωρών του επιστημονικού προγράμματος (αφορά σε ιατρικές επιστημονικές εκδηλώσεις). Στην σελίδα της εκδήλωσης και συμπληρώνοντας τη φόρμα αξιολόγησης, μπορείτε να λάβετε το πιστοποιητικό σας μέσω του πεδίου "ΚΑΤΕΒΑΣΤΕ ΤΟ ΠΙΣΤΟΠΟΙΗΤΙΚΟ ΣΑΣ". Τα πιστοποιητικά δίνονται με τη λήξη της επιστημονικής εκδήλωσης.

Ώρες λειτουργίας Τεχνικής Υποστήριξης:

- καθημερινά 09:00-17:00

- τις ημέρες του event 09:00-21:00

Μπορείτε να επικοινωνήσετε μαζί μας

στο τηλέφωνο +30 210 72 40 039

 

ή μέσω email support@livetime.gr

 

************************************

 

Technical Support is available:

- everyday 09:00-17:00

- at the day of the event 09:00-21:00

For Technical Support please contact us:

Phone: +30 210 72 40 039

Email: support@livetime.gr

 

Event Details
Sponsors